(RTTNews) - Immunic, Inc. (IMUX) Tuesday announced positive outcome from the interim futility analysis of its Phase 3 ENSURE program evaluating the company's lead asset, IMU-838 for the treatment of ...
On Monday, Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and favezelimab. Vibostolimab is being evaluated as an investigational ...
CRANBURY, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced positive ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics’ (NASDAQ: ALLO) interim futility analysis from its registrational ALPHA3 ...
UTRECHT, The Netherlands--(BUSINESS WIRE)--AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today provided a business update and the outcome from ...
I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Allogene Therapeutics (ALLO). The reason why I want to go over this biotech next is because it ...
Alector, Inc. pivots to its Alector Brain Carrier platform, focusing on enhanced blood-brain barrier delivery for neurodegenerative therapeutics. Near-term stock movement hinges on the binary outcome ...
Two phase 3 trials evaluating a subcutaneous (SC) formulation of efgartigimod (efgartigimod alfa and hyaluronidase-qvfc [PH20]), a neonatal Fc receptor blocker, for the treatment of moderate to severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results